Moderna's Influenza Vaccine Candidate Clears Critical FDA Hurdle

FDA accepts Moderna's amended application for mRNA-1010 flu vaccine, reversing earlier refusal. A final decision is expected by August 2026, targeting a launch for the 2026/2027 season.

Moderna has successfully navigated a key regulatory obstacle, bringing its pioneering mRNA-based influenza vaccine closer to reality. The U.S. Food and Drug Administration (FDA) has accepted for review the company's amended application for its candidate, mRNA-1010. This decision marks a significant reversal from the agency's initial refusal to file the submission earlier this year and positions Moderna to potentially launch the first mRNA flu vaccine for the 2026/2027 season.

Strategic Pivot Wins Regulatory Approval

The regulatory journey for mRNA-1010 hit a notable setback on February 10, when the FDA declined to review the application. The agency's primary concern centered on the comparator vaccine used in Moderna's clinical trials, which was deemed not to reflect the current standard of care. In response, Moderna engaged in intensive discussions with regulators and fundamentally revised its approval strategy.

The biotech firm is now pursuing a dual-path regulatory approach. It is seeking traditional licensure for adults aged 50 to 64, while opting for an accelerated approval pathway for seniors aged 65 and older. The latter route will require post-marketing studies to confirm the vaccine's effectiveness. This strategic shift is built upon a substantial data foundation from the Phase III "Glow" trial, which enrolled more than 22,000 participants.

Financial Health and Market Reaction

Despite reporting a net loss of $2.8 billion for the 2025 fiscal year, Moderna's leadership has expressed confidence in the company's near-term trajectory. Management is targeting revenue growth of up to ten percent for 2026, supported by a robust liquidity position exceeding $8 billion at the turn of the year.

Investors have welcomed the positive regulatory development. The company's shares, currently trading at €43.52, are hovering just below their 52-week high of €44.15. Market observers interpret the FDA's acceptance as a crucial positive signal, noting that prominent institutions including Goldman Sachs and RBC Capital had already adjusted their price targets for the biotechnology giant in anticipation of progress.

A final FDA decision on the vaccine's approval is expected by August 5, 2026. A green light would pave the way for the inaugural commercial launch of an mRNA influenza immunization. Concurrently, Moderna is advancing regulatory submissions in other major markets, including Europe, Canada, and Australia, to establish a global footprint for the product.